Evidence map›Paper›PMID 40881429›Full record

ArticleNature synthesis2025

Carbon isotopic labelling of carboxylic acids enabled by organic photoredox-catalysed cyanation.

Zhengbo Zhu, Xuedan Wu, Gerald Thomas Bida, Huaifu Deng, Xinrui Ma, Siran Qian, Zhanhong Wu, Zibo Li, David A Nicewicz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature synthesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Recent advances in [Nuclear medicine and biology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhengbo ZhuDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-0318-6712
Xuedan WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5875-4233
Gerald Thomas BidaBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Huaifu DengBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Xinrui MaBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-7970-3387
Siran QianDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Zhanhong WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Zibo LiBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-1063-0298
David A NicewiczDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-1199-9879

Funding

Novel Catalytic Methods for Efficient Radiolabeling of Un-activated Arene Compounds SupplementR01EB029451 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, NICEWICZ, DAVID A · 2020 to 2023
$2.2M
The development of novel PET/NIRF agents for hyperparathyroidism managementR01DK128447 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM, LAWRENCE THOMAS, WU, ZHANHONG · 2021 to 2024
$2.0M
Development of IDO PET agents for immunotherapyR01CA233904 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, MOSCHOS, STERGIOS · 2019 to 2023
$2.0M
Small Animal PET/CT for Preclinical Imaging ResearchS10OD023611 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2017 to 2017
$835k
NCI NIH HHS R01 CA233904NIBIB NIH HHS R01 EB029451NIDDK NIH HHS R01 DK128447NIH HHS S10 OD023611
6 · The paper itself

Abstract

The application of molecular imaging has advanced personalized medicine and generated a profound impact on patient care. Positron emission tomography and magnetic resonance imaging are among the most widely used imaging modalities, often requiring the isotopic labelling of bioactive molecules to generate the desired imaging probes. Unfortunately, radiochemistry often limits the development of novel agents due to complicated syntheses and the incompatibility of complex molecules. Here, considering the prevalence of carboxylic acids in drug and bioactive molecules, we have developed a method to perform

Identifiers

PMID40881429
PMCPMC12383480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.